Munich Reinsurance Co Stock Corp in Munich Purchases New Shares in Gilead Sciences, Inc. $GILD

Munich Reinsurance Co Stock Corp in Munich purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 608,105 shares of the biopharmaceutical company’s stock, valued at approximately $67,500,000. Gilead Sciences accounts for 1.7% of Munich Reinsurance Co Stock Corp in Munich’s investment portfolio, making the stock its 16th largest holding.

A number of other institutional investors have also added to or reduced their stakes in GILD. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at $26,000. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $30,000. MTM Investment Management LLC lifted its position in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares during the period. Kilter Group LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at about $33,000. Finally, Millstone Evans Group LLC boosted its stake in Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 118 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $144.08 on Friday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a market capitalization of $178.86 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 1.90 and a beta of 0.37. The firm has a 50 day moving average of $138.29 and a 200 day moving average of $125.75. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is 46.68%.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at $25,910,110.97. The trade was a 1.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 309,280 shares of company stock worth $43,935,470 in the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft upped their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Daiwa Securities Group lifted their price objective on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Wolfe Research increased their target price on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, Cantor Fitzgerald raised their price target on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $156.72.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.